Results 231 to 240 of about 88,910 (264)

Sodium glucose co‐transporter 2 inhibitors versus dipeptidyl peptidase‐4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population‐based cohort study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To determine whether sodium glucose co‐transporter 2 inhibitors (SGLT2i) use, compared with dipeptidyl peptidase‐4 inhibitors (DPP4i) use, is associated with the risk of ventricular arrhythmias (VA) among patients with type 2 diabetes. Materials and Methods We conducted a population‐based cohort study using a prevalent new‐user design and
Wang‐Choi Tang, Pauline Reynier, Antonios Douros, Oriana H. Y. Yu, Robert W. Platt, Kristian B. Filion   +5 more
wiley   +1 more source

Performance of Aldosterone-to-renin Ratio Before Washout of Antihypertensive Drugs in Screening of Primary Aldosteronism.

J Clin Endocrinol Metab
Liu X, Hao S, Bian J, Lou Y, Zhang H, Wu H, Cai J, Ma W.   +7 more
europepmc   +1 more source

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

SGLT2 inhibitor or metformin as standard treatment in early‐stage type 2 diabetes? Baseline data in SMARTEST, a novel, decentralised, register‐based randomised trial on prevention of diabetic complications

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Metformin has hitherto not been proven superior to other type 2 diabetes (T2D) medications for the prevention of organ complications. The aim of this study is to report baseline data and blinded interim analyses in the register‐based randomised clinical trial (RRCT) SMARTEST, which compares metformin and the SGLT2 inhibitor dapagliflozin ...
Jan W. Eriksson, Giovanni Fanni, Martin H. Lundqvist, Stefan Jansson, Karin Rådholm, Sheyda Sofizadeh, Vagia Patsoukaki, Albert Nilsson, Daniel Lindholm, Olov Rolandsson, Anna Norhammar, Elisabet Granstam, Björn Eliasson, Louise Bennet, Johan Sundström   +14 more
wiley   +1 more source

Rationale for the Inclusion of β-Blockers Among Major Antihypertensive Drugs in the 2023 European Society of Hypertension Guidelines. [PDF]

Hypertension
Mancia G, Brunström M, Burnier M, Grassi G, Januszewicz A, Kjeldsen SE, Muiesan ML, Thomopoulos C, Tsioufis K, Kreutz R.   +9 more
europepmc   +1 more source

Cardiovascular biomarkers and preeclampsia: A narrative review

European Journal of Clinical Investigation, EarlyView.
Preeclampsia (PE) is a complex pregnancy disorder linked to cardiovascular disease (CVD) through shared risk factors and epidemiological associations. Cardiovascular biomarkers are valuable for predicting, diagnosing and assessing PE, as well as estimating future CVD risk. This review explores current cardiovascular biomarkers used in clinical practice
Johana Ullmo, Madalina Nicoleta Nan, Mónica Cruz‐Lemini, Carmen Garrido‐Gimenez, Judit Platero, Álvaro García‐Osuna, Pablo García‐Manau, Marcel Twickler, Elisa Llurba   +8 more
wiley   +1 more source

Photoplethysmography for Assessing Microcirculation in Hypertensive Patients After Taking Antihypertensive Drugs: A Review. [PDF]

J Multidiscip Healthc
Hu Y, Hu A, Song S.
europepmc   +1 more source

Evaluation of a 3D‐Printed Model as Complete Case Scenario in Undergraduate Dental Education—Diagnosis, Treatment Planning and Clinical Practice

European Journal of Dental Education, EarlyView.
ABSTRACT Introduction 3D‐printed teeth/models are important adjuncts in dental education. Nevertheless, there is a lack of simulated cases to learn and understand complex treatment scenarios, including anamnesis, diagnosis, treatment planning and therapy.
Sebastian Bürklein, Edgar Schäfer, David Donnermeyer   +2 more
wiley   +1 more source

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

European Journal of Haematology, EarlyView.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source